Cover Image
市場調查報告書

人體血清蛋白的全球市場:2016∼2020年

Global Human Albumin Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 362051
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
人體血清蛋白的全球市場:2016∼2020年 Global Human Albumin Market 2016-2020
出版日期: 2016年06月27日 內容資訊: 英文 75 Pages
簡介

白蛋白,雖然在印度和中國等亞太地區各國需要變高,但是用白蛋白產品與其治療使用相關的認知度低使得治療藥的引進推遲。全球人體血清蛋白市場,預計2016∼2020年,以年複合成長率4.97%擴大。

本報告提供全球人體血清蛋白市場現狀與到2020年的預測,市場規模與銷售趨勢,彙整主要供應商的競爭環境與簡介。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 血漿治療藥:概要

  • 血漿的組成
  • 各種血漿治療藥的衍生

第6章 全球血漿治療藥市場

  • 概要
  • 市場規模與預測

第7章 血漿分餾市場

  • 概要
  • 市場規模與預測
  • 主要加入企業

第8章 白蛋白:概要

  • 白蛋白的種類
  • 人體的白蛋白
  • 臨床的使用

第9章 產品研發線

第10章 全球白蛋白市場

第11章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第12章 各用途市場市場區隔

  • 置換療法
  • 藥物製作與給藥
  • 疫苗成分
  • 其他

第13章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第14章 中國的白蛋白市場

第15章 推動市場的要素

  • 對中國的人體血清蛋白的高需求
  • 新的治療適應的摸索
  • 生產能力的擴大

第16章 促進要素的影響

第17章 市場課題

  • 治療費高
  • 病原封鎖策略的擴大
  • 市場上的高法律規章

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • CSL Behring
  • Grifols
  • Baxalta
  • Octapharma
  • Kedrion
  • 其他值得注意的供應商

第21章 附錄

第22章 關於Technavio

目錄
Product Code: IRTNTR9576

About the Human Albumin Market

Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.

The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.

Technavio's analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • CSL Behring
  • Grifols
  • Baxalta
  • Octapharma
  • Kedrion

Other Prominent Vendors

  • AADi
  • Ablynx
  • Albumedix
  • Ampio Pharmaceuticals
  • Azaya Therapeutics
  • Beijing Tiantan
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • ConjuChem
  • GSK
  • Hebei Changshan Biochem Pharma
  • HiMedia Laboratories
  • Hualan Biological Engineering
  • InVittria
  • MedxBio
  • Merck
  • Mitsubishi Tanabe Pharma
  • NantBioScience
  • Novo Nordisk
  • Novozymes
  • Shanghai RAAS Blood Products
  • Sucampo Pharmaceuticals
  • Teva Pharmaceuticals
  • Thermo Fisher Scientific
  • Tianjin SinoBiotech & Beijing Bio-Fortune
  • Ventria Bioscience
  • Yoshitomi Pharmaceutical

Market driver

  • High demand for human albumin in China
  • For a full, detailed list, view our report

Market challenge

  • Spread of pathogenic contaminants
  • For a full, detailed list, view our report

Market trend

  • Rise in non-therapeutic applications
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Plasma therapeutics: An overview

  • Components of blood plasma
  • Derivation of various plasma therapeutics

PART 06: Global plasma therapeutics market

  • Market overview
  • Market size and forecast

PART 07: Plasma fractionation market

  • Overview
  • Market size and forecast
  • Market players

PART 08: Albumin: An overview

  • Types of albumin
  • Albumin in human body
  • Clinical uses

PART 09: Pipeline portfolio

PART 10: Global albumin market

PART 11: Market landscape

  • Global human albumin market
  • Five forces analysis

PART 12: Market segmentation by application

  • Replacement therapy
  • Drug formulation and delivery
  • Vaccine ingredients
  • Others

PART 13: Geographical segmentation

  • Global human albumin market by geographical segmentation 2015-2020
  • Human albumin market in APAC
  • Human albumin market in Americas
  • Human albumin market in EMEA

PART 14: China albumin market

  • Plasma therapeutics market in China
  • Human albumin market in China

PART 15: Market drivers

  • High demand for human albumin in China
  • Exploitation of new therapeutic indications
  • Increase in production capacity

PART 16: Impact of drivers

PART 17: Market challenges

  • High cost of therapy
  • Spread of pathogenic contaminants
  • High regulations in the market

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Novel technologies for albumin-based drug development
  • Rise in non-therapeutic applications
  • Increased development of recombinant albumin

PART 20: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • CSL Behring
  • Grifols
  • Baxalta
  • Octapharma
  • Kedrion
  • Other prominent vendors

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Blood plasma composition
  • Exhibit 03: Plasma proteins composition by percentage share
  • Exhibit 04: Total number of plasma donations in US 2010-2014
  • Exhibit 05: Projected global YoY growth and fractionation capacity of manufacturing units (millions of liter/annum)
  • Exhibit 06: Process of derivation of AAT from plasma
  • Exhibit 07: Global plasma therapeutics market 2015-2020 ($ billions)
  • Exhibit 08: Segmentation of plasma-derived products on revenue 2015
  • Exhibit 09: Global plasma fractionation market 2015-2020 ($ billions)
  • Exhibit 10: Line of treatment of albumin in various diseases
  • Exhibit 11: Pipeline portfolio: Albumin-based therapeutics
  • Exhibit 12: Segmentation of global albumin market
  • Exhibit 13: Global human albumin market 2015-2020 ($ billions)
  • Exhibit 14: Global human albumin market 2015-2020 (tons)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of human albumin market based on application
  • Exhibit 17: Segmentation of global human albumin market based on geography 2015
  • Exhibit 18: Human albumin market revenue by geography 2015-2020 ($ billions)
  • Exhibit 19: Human albumin market by geography 2015-2020
  • Exhibit 20: Human albumin market in APAC 2015-2020 ($ billions)
  • Exhibit 21: Albumin market in China in global albumin market 2015
  • Exhibit 22: Human albumin market in Americas 2015-2020 ($ billions)
  • Exhibit 23: Albumin market in US 2015
  • Exhibit 24: Human albumin market in EMEA 2015-2020 ($ millions)
  • Exhibit 25: Global human albumin market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 26: Segmentation of various plasma products 2015
  • Exhibit 27: Plasma therapeutics market in China 2015-2020 ($ billions)
  • Exhibit 28: Human albumin market in China 2015-2020 ($ billions)
  • Exhibit 29: Domestic and imported albumin in China 2015
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: CSL Behring: Segmentation by revenue 2015
  • Exhibit 33: CSL Behring: YoY revenue and growth rate of albumin products 2013-2015 ($ millions)
  • Exhibit 34: CSL Behring: Key takeaways
  • Exhibit 35: Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
  • Exhibit 36: Grifols: Key takeaways
  • Exhibit 37: Baxalta: Segmentation by revenue 2015
  • Exhibit 38: Baxalta: YoY revenue comparison of Biotherapeutics segment 2013-2015 ($ millions)
  • Exhibit 39: Baxalta: Geographic segmentation of BioTherapeutics 2015
  • Exhibit 40: Baxalta: Key takeaways
  • Exhibit 41: Octapharma: Key takeaways
  • Exhibit 42: Kedrion: Key takeaways
Back to Top